MDR Rule 12: The Hazardous-Manner Test Decides IIa or IIb

Annex VIII, Rule 12 of the EU Medical Device Regulation starts every active device that administers or removes a medicinal product, body liquid, or other substance to or from the body at Class IIa. It climbs to Class IIb only when that administration or removal happens in a potentially hazardous manner. The mistake teams make is treating that second step as a property of the device category — infusion pumps are IIb, nebulizers are IIa — when Annex VIII actually asks a fact-specific question about the substance, the body site, and how the device applies it. Two devices in the same product family can answer that question differently.

What Rule 12 actually covers

Rule 12 reaches any active device — one that depends on a source of energy other than that generated by the human body or gravity — whose intended purpose is to administer and/or remove a medicinal product, body liquid, or other substance to or from the body. In practice that is a wide family: infusion pumps, nebulizers and other inhalation-delivery systems, dialysis machines, anaesthesia delivery devices, and extracorporeal circuits that move blood or other body fluids outside the body. It sits alongside Rule 13's catch-all for active devices that no more specific rule reaches, and ahead of it in the analysis — a manufacturer only reaches Rule 13's Class I default after confirming Rule 12 and the other specific active-device rules do not apply.

The three-factor hazard test

Annex VIII's operative language ties the Class IIb trigger to three factors taken together: the nature of the substance involved, the part of the body concerned, and the mode of application. None of the three is dispositive alone, and the European Commission's classification guidance, MDCG 2021-24, does not supply a bright-line numeric threshold for “potentially hazardous.” That is a deliberate design choice in the regulation — and an operational headache for manufacturers who want a checklist answer. In current practice, devices such as ambulatory infusion pumps delivering insulin or other high-alert medications are commonly classified Class IIb, because a dosing error at the point of administration carries acute clinical risk; a device delivering saline or a wide-therapeutic-index fluid under the same general infusion-pump category can remain Class IIa. The device, not the category label on its marketing material, is what gets tested.

• Nature of the substance. A high-alert medication with a narrow therapeutic index or a steep dose-response curve pushes toward IIb; a low-risk fluid does not, even in an otherwise identical delivery platform.
• Part of the body concerned. Administration or removal at a site where an error is harder to detect or correct — the central circulation, for example — weighs differently than a site that tolerates a wider margin for error.
• Mode of application. A continuous, unsupervised, or programmable delivery mode carries more hazard exposure than an intermittent, clinician-controlled one, independent of what substance is involved.
• The three factors interact. A device that looks low-risk on any single factor can still be IIb once the combination is assessed against its actual intended use — which is why the rationale, not just the conclusion, belongs in the technical documentation.

A notified body is not auditing your product category. It is testing whether your classification rationale actually works through the substance, the body site, and the mode of application for the device in front of it. Why the written rationale matters more than the label

Where manufacturers misroute the analysis

The most common error is skipping straight to a category assumption — “it's an infusion pump, so it's IIb” — without running the three-factor test against the specific device. The second most common error is confusing Rule 12 with its neighbors. Rule 13 only reaches active devices that no other rule in the chapter addresses; it is not a fallback a manufacturer can choose instead of working through Rule 12 when the device administers or removes a substance. Rule 14 is a different mechanism altogether — it applies when a device incorporates, as an integral part, a substance that would itself be a medicinal product if used separately, and it forces Class III regardless of how the hazard test under Rule 12 would have come out. A device can trigger Rule 14 and never reach the Rule 12 analysis at all, because Rule 14 governs a built-in substance, not a delivery function. Getting the rule selection wrong upstream sends the conformity assessment route down the wrong path before a notified body ever sees the file.

None of this is exotic, but it is easy to under-scope. A classification memo that states the conclusion without working through the substance, the body site, and the mode of application together is the kind of file a notified body sends back with questions — and a borderline Rule 12 call is exactly where that happens, because the regulation gives no numeric line to point to. Building the rationale as part of your broader risk management file under ISO 14971 and your medical device regulatory strategy keeps the classification defensible the first time, instead of after a deficiency letter.